bioRxivCancer BiologyPreprint
Thymidine rescues ATR kinase inhibition induced deoxyuridine contamination in genomic DNA, cell death, and Type 1 interferon expression
N. Sugitani, F. P. Vendetti, A. J. Cipriano, P. Pandya, J. J. Deppas, T. N. Moiseeva, S. Schamus-Haynes, Y. Wang, D. Palmer, H. U. Osmanbeyoglu, A. Bostwick, N. W. Snyder, Y.-N. Gong, K. M. Aird, G. M. Delgoffe, J. H. Beumer, C. J. Bakkenist
Abstract
ATR kinase is a central regulator of the DNA damage response (DDR) and cell cycle checkpoints. ATR kinase inhibitors (ATRis) combine with radiation to generate CD8+ T cell-dependent responses in mouse models of cancer. We show that ATRis induce CDK1-dependent origin firing across active replicons in CD8+ T cells activated ex vivo while simultaneously decreasing the activity of rate-limiting enzymes for nucleotide biosynthesis. These pleiotropic effects of ATRi induce deoxyuridine (dU) contamination in genomic DNA, R loops, RNA-DNA polymerase collisions, and type-1 interferons (IFN-1). Remarkably, thymidine rescues ATRi-induced dU contamination, cell death, and IFN-1 expression in proliferating CD8+ T cells. Thymidine also rescues ATRi-induced cancer cell death. We propose that ATRi-induced dU contamination contributes to dose-limiting leukocytopenia and inflammation in the clinic and CD8+ T cell dependent anti-tumor responses in mouse models. We conclude that ATR is essential to limit dU contamination in genomic DNA and IFN-1 expression.
- organism: mouse
- assay: bulk RNA-seq
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- ATR kinase inhibitors induce mitochondrial fission in CD8+ T cells and impair immune memory in vivo
Frank P. Vendetti, Carina R. Sclafani, … Christopher J. Bakkenist·bioRxiv·May 26, 2026
- Short-course but not prolonged treatment with ATR inhibitor AZD6738 integrates with radiotherapy to generate a tumor antigen-specific CD8+ T cell expansion in the periphery
F. P. Vendetti, D. A. Clump, … C. J. Bakkenist·bioRxiv·Apr 11, 2022
- Deoxyuridine-rich cytoplasmic DNA antagonizes STING-dependent innate immune responses and sensitizes resistant tumors to anti-PD-L1 therapy
Pinakin Pandya, Frank P. Vendetti, … Christopher J. Bakkenist·bioRxiv·Apr 4, 2024
- A consensus set of genetic vulnerabilities to ATR inhibition
Nicole Hustedt, Alejandro Álvarez-Quilón, … Daniel Durocher·Open BiologyPeer-reviewed·Sep 1, 2019
- DNA-PK enforces the S/G2 checkpoint in ATM-deficient cells to limit ATR inhibitor efficacy
Timothy B. Branigan, Roshen Alharthi, … Geoffrey Ira Shapiro·bioRxiv·Oct 28, 2026
- ATR Inhibitors as Potent Modulators of DNA End Resection Capacity
D. Dibitetto, J. R. Sims, … M. B. Smolka·bioRxiv·Jan 13, 2020